Abstract
Before the advent of molecular-targeted agents, immunotherapy using cytokines, such as interferon-α (IFN-α) and interleukin-2 (IL-2), had been the mainstay of treatment for patients with metastatic renal cell carcinoma (mRCC), and this therapy may still be occasionally recommended for such patients. In this report, we present two cases of mRCC who were treated with very-low-dose IL-2 therapy and subsequently achieved complete response (CR). Both cases received adjuvant IFN-α therapy following radical nephrectomy; however, multiple lung metastases developed 4 and 12 months after surgery, and low-dose IL-2 (0.7 million U/day) was then administered twice per week for 14 and 35 months, respectively. In both cases, metastatic lesions completely regressed 3 and 20 months after the start of IL-2 therapy, and these responses have persisted for 81 and 67 months, respectively, to date. These findings suggest that immunotherapy with IL-2, even at a very-low-dose setting, may achieve the induction of CR in mRCC; accordingly, IL-2-based immunotherapy should be considered as the initial treatment for appropriately selected patients with mRCC.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Herrmann E, Bierer S, Wülfing C. Update on systemic therapies of metastatic renal cell carcinoma. World J Urol. 2010;28:303–9.
Naito S, Yamamoto N, Takayama T, Muramoto M, Shinohara N, Nishiyama K, et al. Prognosis of Japanese metastatic renal cell carcinoma patients in the cytokine era: a cooperative group report of 1463 patients. Eur Urol. 2010;57:317–25.
Akaza H, Kawai K, Tsukamoto T, Fujioka T, Tomita Y, Kitamura T, et al. Successful outcomes using combination therapy of interleukin-2 and interferon-alpha for renal cell carcinoma patients with lung metastasis. Jpn J Clin Oncol. 2010;40:684–9.
Miyake H, Kurahashi T, Takenaka A, Inoue TA, Fujisawa M. Clinical outcome of combined immunotherapy with interferon-alpha and low-dose interleukin-2 for Japanese patients with metastatic renal cell carcinoma. Urol Oncol. 2009;27:598–603.
Koneru R, Hotte SJ. Role of cytokine therapy for renal cell carcinoma in the era of targeted agents. Curr Oncol. 2009;16:S40–4.
McDermott DF, Atkins MB. Immunotherapy of metastatic renal cell carcinoma. Cancer J. 2008;14:320–4.
Klapper JA, Downey SG, Smith FO, Yang JC, Hughes MS, Kammula US, et al. High-dose interleukin-2 for the treatment of metastatic renal cell carcinoma: a retrospective analysis of response and survival in patients treated in the surgery branch at the National Cancer Institute between 1986 and 2006. Cancer. 2008;113:293–301.
Yang JC, Sherry RM, Steinberg SM, Topalian SL, Schwartzentruber DJ, Hwu P, et al. Randomized study of high-dose and low-dose interleukin-2 in patients with metastatic renal cancer. J Clin Oncol. 2003;21:3127–32.
Vlasveld LT, Hekman A, Vyth-Dreese FA, Rankin EM, Scharenberg JG, Voordouw AC, et al. A phase I study of prolonged continuous infusion of low dose recombinant interleukin-2 in melanoma and renal cell cancer. Part II: immunological aspects. Br J Cancer. 1993;68:559–67.
Caligiuri MA. Low-dose recombinant interleukin-2 therapy: rationale and potential clinical applications. Semin Oncol. 1993;20:3–10.
Buzio C, Andrulli S, Santi R, Pavone L, Passalacqua R, Potenzoni D, et al. Long-term immunotherapy with low-dose interleukin-2 and interferon-alpha in the treatment of patients with advanced renal cell carcinoma. Cancer. 2001;92:2286–96.
Casamassima A, Picciariello M, Quaranta M, Berardino R, Ranieri C, Paradiso A, et al. C-reactive protein: a biomarker of survival in patients with metastatic renal cell carcinoma treated with subcutaneous interleukin-2 based immunotherapy. J Urol. 2005;173:52–5.
Maruyama R, Yamana K, Itoi T, Hara N, Bilim V, Nishiyama T, et al. Absence of Bcl-2 and Fas/CD95/APO-1 predicts the response to immunotherapy in metastatic renal cell carcinoma. Br J Cancer. 2006;95:1244–9.
Miyake H, Sakai I, Muramaki M, Kurahashi T, Takenaka A, Fujisawa M. Prediction of response to combined immunotherapy with interferon-alpha and low-dose interleukin-2 in metastatic renal cell carcinoma: expression patterns of potential molecular markers in radical nephrectomy specimens. Int J Urol. 2009;16:465–71.
Mizumori O, Zembutsu H, Kato Y, Tsunoda T, Miya F, Morizono T, et al. Identification of a set of genes associated with response to interleukin-2 and interferon-alpha combination therapy for renal cell carcinoma through genome-wide gene expression profiling. Exp Ther Med. 2010;1:955–61.
Author information
Authors and Affiliations
Corresponding author
About this article
Cite this article
Harada, Ki., Miyake, H., Kurahashi, T. et al. Long-term complete response to very-low-dose interleukin-2 therapy in patients with metastatic renal cell carcinoma: report of two cases. Clin Exp Nephrol 15, 966–969 (2011). https://doi.org/10.1007/s10157-011-0518-x
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10157-011-0518-x